tradingkey.logo
tradingkey.logo
Search

Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of Nereus™ For The Prevention Of Vomiting Induced By Glp-1 Receptor Agonists

ReutersApr 8, 2026 9:11 PM

- Vanda Pharmaceuticals Inc VNDA.O:

  • VANDA PHARMACEUTICALS ANNOUNCES INITIATION OF THE THETIS STUDY, A CLINICAL TRIAL OF NEREUS™ FOR THE PREVENTION OF VOMITING INDUCED BY GLP-1 RECEPTOR AGONISTS

  • VANDA PHARMACEUTICALS INC - TOPLINE RESULTS FROM THETIS STUDY EXPECTED BY Q4 2026

  • VANDA PHARMACEUTICALS INC: PHASE 2 STUDY SUCCEEDED AND MET ITS PRIMARY ENDPOINT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI